Abilify Manufactured by Bristol Myers Squibb
Links shared publicly online about this topic
Bristol-Myers Extends Abilify Sales Pact - WSJ.com
feeds.wsjonline.com — “Bristol-Myers Squibb will sell the psychiatric drug Abilify into 2015 under a deal with Otsuka Pharmaceutical.” View full resource at feeds.wsjonline.com
Most Recently Shared on April 6, 2009 at 2:23 pm By:
Bristol-Meyers, Otsuka Extend Deal http://tinyurl.com/dk2hvu
News: UK's NICE wants more data on the effectiveness of Bristol-Myers Squibb's schizophrenia drug Abilify http://bit.ly/9Zrcsf - #health
reuters.com — “News: UK's NICE wants more data on the effectiveness of Bristol-Myers Squibb's schizophrenia drug Abilify http://bit.ly/9Zrcsf - #health” View full resource at reuters.com
Most Recently Shared on September 10, 2010 at 3:45 am By:
Hisham Rana, MD Doctor and Physician
News: UK's NICE wants more data on the effectiveness of Bristol-Myers Squibb's schizophrenia drug Abilify http://bit.ly/9Zrcsf - #health
Abilify Treats Autism-Related Irritability
webmd.com — “The drug abilify (aripiprazole) may help ease the symptoms of irritability related to autism in children and adolescents, a study shows.” View full resource at webmd.com
Most Recently Shared on November 30, 2009 at 8:08 pm By:
webMD: Abilify Treats Autism-Related Irritability http://bit.ly/6ylRJR Full http://bit.ly/5EFNtO
Abilify approved for irritability associated with autistic disorder - MPR
empr.com — “The FDA has approved Abilify (aripiprazole, from Bristol-Myers Squibb and Otsuka) for the treatment of irritability associated with autistic disorder in pediatric patients 6"17 years of age, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.” View full resource at empr.com
Most Recently Shared on November 23, 2009 at 3:41 pm By:
MPR News: Abilify approved for irritability associated with autistic disorder: The FDA has approved Abilify (aripip... http://bit.ly/510cxX
Abilify approved as adjunct for maintenance treatment of bipolar disorder - MPR
empr.com — “Bristol-Myers Squibb and Otsuka announced that Abilify (aripiprazole) has been approved by the FDA as an adjunct to lithium or valproate for the maintenance treatment of bipolar I disorder.” View full resource at empr.com
Most Recently Shared on February 22, 2011 at 8:04 pm By:
MPR News: Abilify approved as adjunct for maintenance treatment of bipolar disorder: Bristol-Myers Squibb and Ot... http://bit.ly/ffWVy7
FDA approves sNDA for pediatric autism drug ABILIFY
news-medical.net — “Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.” View full resource at news-medical.net
Most Recently Shared on November 21, 2009 at 9:29 am By:
Obesity News: FDA approves sNDA for pediatric autism drug ABILIFY: Bristol-Myers Squibb Company an.. http://twurl.nl/kl8lfe
Bristol-Myers Squibb, Oncolys complete license agreement for festinavir
news-medical.net — “Bristol-Myers Squibb Company and Oncolys BioPharma Inc., a privately held biotechnology company based in Japan, announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire exclusive worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV.” View full resource at news-medical.net
Most Recently Shared on December 20, 2010 at 6:38 pm By:
HIV/AIDS News: Bristol-Myers Squibb, Oncolys complete license agreement for festinavir: Bristol-Myers Squibb Com... http://bit.ly/ggbWKS
Quebec agrees reimbursement of ABILIFY for schizophrenia treatment in public drug plans
news-medical.net — “Bristol-Myers Squibb Canada is pleased to announce that Quebec has recognized the value of ABILIFY (aripiprazole) for the treatment of schizophrenia and related psychotic disorders in adults and has agreed to list ABILIFY as a reimbursed full benefit on the Quebec public drug plans as of October 14, 2010.” View full resource at news-medical.net
Most Recently Shared on October 27, 2010 at 8:46 am By:
Quebec agrees reimbursement of ABILIFY for schizophrenia treatment in public drug plans: Bristol-Myers Squibb Cana... http://bit.ly/bY3JVo
U.S. Food And Drug Administration Approves ABILIFY® (aripiprazole) For The Treatment Of Irritability Associated With Autistic Disorder In Patients
medicalnewstoday.com — “(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Appl” View full resource at medicalnewstoday.com
Most Recently Shared on November 28, 2009 at 11:28 am By:
MNT Clinical Trials Health News
U.S. Food And Drug Administration Approves ABILIFY® (aripiprazole) For The Treatment Of Irritability Associated.. http://bit.ly/51H21G
Abilify approved as adjunct for maintenance treatment of bipolar disorder - ONA
oncologynurseadvisor.com — “Bristol-Myers Squibb and Otsuka announced that Abilify (aripiprazole) has been approved by the FDA as an adjunct to lithium or valproate for the maintenance treatment of bipolar I disorder.” View full resource at oncologynurseadvisor.com
Most Recently Shared on February 22, 2011 at 7:15 pm By:
OncologyNurseAdvisor Nursing, Medical Education, Medical Publisher, and Oncology
Abilify approved as adjunct for maintenance treatment of bipolar disorder http://goo.gl/fb/6ZuIk
U.S. Food and Drug Administration Approves Abilify (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)
drugs.com — “Abilify (aripiprazole) is used to treat irritability associated with autistic disorder in pediatric patients. Includes Abilify side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on November 24, 2009 at 12:10 am By:
FDA Approves Abilify for Irritability Associated with Autistic Disorder in Pediatric Patients - http://bit.ly/62jJ8P
FDA panel recommends change to label of Abilify - Related Stories - AAP SmartBrief
smartbrief.com — “An FDA panel unanimously concluded that the label of Bristol-Myers Squibb's antipsychotic Abilify for use in children lacks information on the risk of excessive weight gain. The panel advised Bristol-Myers to keep monitoring pediatric use of the drug and move data on its metabolic effect on children” View full resource at smartbrief.com
Most Recently Shared on December 11, 2009 at 6:07 am By:
Clara Song Doctor, Pediatrician, and Physician
FDA panel recommends change to label of Abilify http://sbne.ws/r/3qaF
FDA approves Abilify for treating autistic irritability - Related Stories - AAP SmartBrief
smartbrief.com — “The FDA approved Abilify for treating irritability in autistic children ages 6 to 17 years. Bristol-Myers Squibb said approval was based on data from two Phase III studies that showed Abilify, when compared with a placebo, significantly improved scores on the Irritability subscale of the Aberrant Be” View full resource at smartbrief.com
Most Recently Shared on November 24, 2009 at 2:24 am By:
Clara Song Doctor, Pediatrician, and Physician
FDA approves Abilify for treating autistic irritability http://sbne.ws/r/3kvd
Experts question long-term efficacy of Abilify for bipolar disorder - Related Stories - AANP SmartBrief
smartbrief.com — “Researchers cited a lack of evidence for the effectiveness of Otsuka Pharmaceutical and Bristol-Myers Squibb's Abilify as maintenance therapy for bipolar disorder. Only one randomized, double-blind clinical trial evaluated Abilify's long-term benefits, and that study had limitations, researchers no--” View full resource at smartbrief.com
Most Recently Shared on May 4, 2011 at 3:33 pm By:
ABILIFY® (aripiprazole) Approved for Maintenance Treatment of Bipolar I Disorder as an Adjunct to Either Lithium or Valproate - Business Wire - Wire - BradentonHerald.com
bradenton.com — “Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. , announced today that the U.S. Food and Drug Administration (FDA) has approved ABILIFY ® (aripiprazole) as an adjunct to the mood stabilizers lithium or valproate for the maintenance treatment of Bipolar I Disorder.” View full resource at bradenton.com
Most Recently Shared on February 17, 2011 at 5:02 pm By:
Peter H Brown Doctor and Psychologist
ABILIFY® (aripiprazole) Approved for Maintenance Treatment of Bipolar I ... http://bit.ly/fnyJ5i #bipolar
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
WSJ Health
Health news coverage from the Wall Street Journal
-
Hisham Rana, MD
I tweet mostly about medicine, politics, and tech. Please see the link for a disclaimer and other policies.
-
Heart Health
Get the latest news, information, and research on your heart. Re-tweet if you want.
Advertisement
